NEW YORK (GenomeWeb News) – Merck Serono, the biopharmaceutical division of Merck KGaA, today said that it has spun out a bioinformatics firm, Quartz Bio, from its Entrepreneur Partnership Program launched earlier this year.

Quartz Bio will be located in the Blue Box offices of FONGIT, a start-up accelerator located in Geneva, Switzerland. It will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."